Blood-Borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium

Lin, 2009, Blood group antigens and normal red blood cell physiology: A Canadian Blood Services Research and Development symposium, Transfus Med Rev, 23, 292, 10.1016/j.tmrv.2009.06.004 Pavenski, 2012, Red blood cell storage lesions and related transfusion issues: A Canadian Blood Services Research and Development symposium, Transfus Med Rev, 26, 68, 10.1016/j.tmrv.2011.07.003 Saidenberg, 2010, Transfusion-related acute lung injury (TRALI): A Canadian Blood Services Research and Development Symposium, Transfus Med Rev, 24, 305, 10.1016/j.tmrv.2010.05.005 Sheffield, 2005, Blood group biochemistry: A Canadian Blood Services Research and Development Symposium, Transfus Med Rev, 19, 295, 10.1016/j.tmrv.2005.04.005 Shehata, 2007, Cellular therapies: A Canadian Blood Services Research and Development Symposium, Transfus Med Rev, 21, 317, 10.1016/j.tmrv.2007.05.007 Tinmouth, 2006, Platelet immunopathology and therapy: A Canadian Blood Services Research and Development Symposium, Transfus Med Rev, 20, 294, 10.1016/j.tmrv.2006.05.008 Webert, 2014, Platelet utilization: A Canadian Blood Services Research and Development Symposium, Transfus Med Rev, 28, 84, 10.1016/j.tmrv.2014.01.002 Zeller, 2015, Plasma and Plasma Protein Product Transfusion: A Canadian Blood Services Centre for Innovation Symposium, Transfus Med Rev, 29, 181, 10.1016/j.tmrv.2015.03.003 O'Brien, 2012, Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services, Vox Sang, 103, 83, 10.1111/j.1423-0410.2012.01584.x Montgomery, 2006, Transfusion-associated transmission of West Nile virus, United States 2003 through 2005, Transfusion, 46, 2038, 10.1111/j.1537-2995.2006.01030.x O'Brien, 2010, West Nile virus in 2006 and 2007: the Canadian Blood Services' experience, Transfusion, 50, 1118, 10.1111/j.1537-2995.2009.02550.x World Health Organization Bern, 2009, An estimate of the burden of Chagas disease in the United States, Clin Infect Dis, 49, e52, 10.1086/605091 AABB O'Brien, 2014, Evaluation of selective screening of donors for antibody to Trypanosoma cruzi: Seroprevalence of donors who answer “no” to risk questions, Transfusion, 54, 863, 10.1111/trf.12219 Vannier, 2012, Human babesiosis, N Engl J Med, 366, 2397, 10.1056/NEJMra1202018 Food and Drug Administration Herwaldt, 2011, Transfusion-associated babesiosis in the United States: A description of cases, Ann Intern Med, 155, 509, 10.7326/0003-4819-155-8-201110180-00362 Hewitt, 2014, Hepatitis E virus in blood components: A prevalence and transmission study in southeast England, Lancet, 384, 1766, 10.1016/S0140-6736(14)61034-5 Leparc-Goffart, 2014, Chikungunya in the Americas, Lancet, 383, 514, 10.1016/S0140-6736(14)60185-9 Gabriele-Rivet, 2015, Different Ecological Niches for Ticks of Public Health Significance in Canada, PLoS One, 10, e0131282, 10.1371/journal.pone.0131282 O'Brien, 2016, Seroprevalence of Babesia microti infection in Canadian blood donors, Transfusion, 56, 237, 10.1111/trf.13339 Leach Bennett, 2011, Proceedings of a consensus conference: Risk-Based Decision Making for Blood Safety, Transfus Med Rev, 25, 267, 10.1016/j.tmrv.2011.05.002 Alliance of Blood Operators Stein, 2011, Risk-based decision-making for blood safety: preliminary report of a consensus conference, Vox Sang, 101, 277, 10.1111/j.1423-0410.2011.01526.x Menitove, 2014, How safe is safe enough, who decides and how? From a zero-risk paradigm to risk-based decision making, Transfusion, 54, 753, 10.1111/trf.12569 Dodd, 2012, Emerging pathogens and their implications for the blood supply and transfusion transmitted infections, Br J Haematol, 159, 135, 10.1111/bjh.12031 Diack, 2014, Variant CJD. 18 years of research and surveillance, Prion, 8, 286, 10.4161/pri.29237 Sharp, 2011, Origins of HIV and the AIDS pandemic, Cold Spring Harb Perspect Med, 1, a006841, 10.1101/cshperspect.a006841 Berry, 2015, Identification of new respiratory viruses in the new millennium, Viruses, 7, 996, 10.3390/v7030996 Sridhar, 2015, Hepatitis E: A disease of reemerging importance, J Formos Med Assoc, 114, 681, 10.1016/j.jfma.2015.02.003 Allen, 1987, Transmission of human immunodeficiency virus (HIV) by blood and blood components, 37 Dodd, 2015, Keeping Blood Transfusion Safe From West Nile Virus: American Red Cross Experience, 2003 to 2012, Transfus Med Rev, 29, 153, 10.1016/j.tmrv.2015.03.001 Stramer, 2009, Emerging infectious disease agents and their potential threat to transfusion safety, Transfusion, 49, 1S, 10.1111/j.1537-2995.2009.02279.x Stramer, 2013, AABB Transfusion-Transmitted Diseases Emerging Infectious Diseases Subgroup: Transfusion-transmitted emerging infectious diseases: 30 years of challenges and progress, Transfusion, 53, 2375, 10.1111/trf.12371 Jaunmuktane, 2015, Evidence for human transmission of amyloid-beta pathology and cerebral amyloid angiopathy, Nature, 525, 247, 10.1038/nature15369 Bhatt, 2013, The global distribution and burden of dengue, Nature, 496, 504, 10.1038/nature12060 Stramer, 2012, Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico, Transfusion, 52, 1657, 10.1111/j.1537-2995.2012.03566.x Petersen, 2014, Chikungunya virus: new risk to transfusion safety in the Americas, Transfusion, 54, 1911, 10.1111/trf.12790 Cerus Corporation Gonzalez, 2005, Ebola virus circulation in Africa: A balance between clinical expression and epidemiological silence, Bull Soc Pathol Exot, 98, 210 Martines, 2015, Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses, J Pathol, 235, 153, 10.1002/path.4456 Ansari, 2014, Clinical features and pathobiology of Ebolavirus infection, J Autoimmun, 55, 1, 10.1016/j.jaut.2014.09.001 Shears, 2015, Ebola virus disease in Africa: epidemiology and nosocomial transmission, J Hosp Infect, 90, 1, 10.1016/j.jhin.2015.01.002 Lanini, 2015, Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?, Lancet Infect Dis, 15, 738, 10.1016/S1473-3099(15)70106-4 World Health Organization Belluz, 2014 Ginsburg, 2014 Gostin, 2015, A retrospective and prospective analysis of the west African Ebola virus disease epidemic: Robust national health systems at the foundation and an empowered WHO at the apex, Lancet, 385, 1902, 10.1016/S0140-6736(15)60644-4 Nyenswah, 2015, Community quarantine to interrupt Ebola virus transmission - Mawah Village, Bong County, Liberia, August-October, 2014, MMWR Morb Mortal Wkly Rep, 64, 179 Henao-Restrepo, 2015, Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomised trial, Lancet, 386, 857, 10.1016/S0140-6736(15)61117-5 World Health Organization Alexander, 2015, What factors might have led to the emergence of Ebola in West Africa?, PLoS Negl Trop Dis, 9, e0003652, 10.1371/journal.pntd.0003652 Woolhouse, 2015, Lessons from Ebola: Improving infectious disease surveillance to inform outbreak management, Sci Transl Med, 7, 307rv305, 10.1126/scitranslmed.aab0191 Fineberg, 2013, The paradox of disease prevention: celebrated in principle, resisted in practice, JAMA, 310, 85, 10.1001/jama.2013.7518 Fallah, 2015, Strategies to prevent future Ebola epidemics, Lancet, 386, 131, 10.1016/S0140-6736(15)61233-8 Bennett, 2015 McCulloch, 1960, The radiation sensitivity of normal mouse bone marrow cells, determined by quantitative marrow transplantation into irradiated mice, Radiat Res, 13, 115, 10.2307/3570877 Gregory, 1978, Three stages of erythropoietic progenitor cell differentiation distinguished by a number of physical and biologic properties, Blood, 51, 527, 10.1182/blood.V51.3.527.527 Mountford, 2011, In vitro production of red blood cells, Transfus Apher Sci, 45, 85, 10.1016/j.transci.2011.06.007 Fibach, 1989, Proliferation and maturation of human erythroid progenitors in liquid culture, Blood, 73, 100, 10.1182/blood.V73.1.100.100 Fibach, 1991, Growth of human normal erythroid progenitors in liquid culture: A comparison with colony growth in semisolid culture, Int J Cell Cloning, 9, 57, 10.1002/stem.5530090108 Douay, 2009, Ex vivo generation of human red blood cells: A new advance in stem cell engineering, Methods Mol Biol, 482, 127, 10.1007/978-1-59745-060-7_8 Thomson, 1998, Embryonic stem cell lines derived from human blastocysts, Science, 282, 1145, 10.1126/science.282.5391.1145 Kaufman, 2001, Hematopoietic colony-forming cells derived from human embryonic stem cells, PNAS, 98, 10716, 10.1073/pnas.191362598 Takahashi, 2007, Induction of pluripotent stem cells from fibroblast cultures, Nat Protoc, 2, 3081, 10.1038/nprot.2007.418 Takahashi, 2007, Induction of pluripotent stem cells from adult human fibroblasts by defined factors, Cell, 131, 861, 10.1016/j.cell.2007.11.019 Lengerke, 2009, Hematopoietic development from human induced pluripotent stem cells, Ann N Y Acad Sci, 1176, 219, 10.1111/j.1749-6632.2009.04606.x Choi, 2009, Hematopoietic and endothelial differentiation of human induced pluripotent stem cells, Stem Cells, 27, 559, 10.1002/stem.20080922 Kobari, 2012, Human induced pluripotent stem cells can reach complete terminal maturation: In vivo and in vitro evidence in the erythropoietic differentiation model, Haematologica, 97, 1795, 10.3324/haematol.2011.055566 Huang, 2014, Extensive ex vivo expansion of functional human erythroid precursors established from umbilical cord blood cells by defined factors, Mol Ther, 22, 451, 10.1038/mt.2013.201 Chang, 2011, Generation and characterization of erythroid cells from human embryonic stem cells and induced pluripotent stem cells: An overview, Stem Cells Int, 2011, 791604, 10.4061/2011/791604 Mazurier, 2011, Red blood cells from induced pluripotent stem cells: Hurdles and developments, Curr Opin Hematol, 18, 249, 10.1097/MOH.0b013e3283476129 Trakarnsanga, 2014, Induction of adult levels of beta-globin in human erythroid cells that intrinsically express embryonic or fetal globin by transduction with KLF1 and BCL11A-XL, Haematologica, 99, 1677, 10.3324/haematol.2014.110155 Kurita, 2013, Establishment of immortalized human erythroid progenitor cell lines able to produce enucleated red blood cells, PLoS One, 8, e59890, 10.1371/journal.pone.0059890 Cambot, 2013, In vitro generated Rh(null) red cells recapitulate the in vivo deficiency: A model for rare blood group phenotypes and erythroid membrane disorders, Am J Hematol, 88, 343, 10.1002/ajh.23414 Giarratana, 2011, Proof of principle for transfusion of in vitro-generated red blood cells, Blood, 118, 5071, 10.1182/blood-2011-06-362038 Mittra, 2015, Identifying viable regulatory and innovation pathways for regenerative medicine: A case study of cultured red blood cells, N Biotechnol, 32, 180, 10.1016/j.nbt.2014.07.008 Sanger, 1977, DNA sequencing with chain-terminating inhibitors, PNAS, 74, 5463, 10.1073/pnas.74.12.5463 Chen, 2014, DNA polymerases drive DNA sequencing-by-synthesis technologies: both past and present, Front Microbiol, 5, 305, 10.3389/fmicb.2014.00305 Anderson, 1981, Sequence and organization of the human mitochondrial genome, Nature, 290, 457, 10.1038/290457a0 Lander, 2001, Initial sequencing and analysis of the human genome, Nature, 409, 860, 10.1038/35057062 Venter, 2001, The sequence of the human genome, Science, 291, 1304, 10.1126/science.1058040 Pickrell, 2012, Next generation sequencing methodologies--an overview, Adv Protein Chem Struct Biol, 89, 1, 10.1016/B978-0-12-394287-6.00001-X Pareek, 2011, Sequencing technologies and genome sequencing, J Appl Genet, 52, 413, 10.1007/s13353-011-0057-x Rusk, 2015, MinION takes center stage, Nat Methods, 12, 12, 10.1038/nmeth.3244 Naccache, 2014, A cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samples, Genome Res, 24, 1180, 10.1101/gr.171934.113 Wilson, 2014, Actionable diagnosis of neuroleptospirosis by next-generation sequencing, N Engl J Med, 370, 2408, 10.1056/NEJMoa1401268 Naccache, 2015, Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next-generation sequencing, Clin Infect Dis, 60, 919, 10.1093/cid/ciu912 Greninger, 2015, Rapid metagenomic identification of viral pathogens in clinical samples by real-time nanopore sequencing analysis, Genome Med, 7, 99, 10.1186/s13073-015-0220-9 Xu, 2013, Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing, PNAS, 110, 10264, 10.1073/pnas.1303744110 Naccache, 2013, The perils of pathogen discovery: Origin of a novel parvovirus-like hybrid genome traced to nucleic acid extraction spin columns, J Virol, 87, 11966, 10.1128/JVI.02323-13 Pietersz, 2014, Bacterial contamination in platelet concentrates, Vox Sang, 106, 256, 10.1111/vox.12098 AABB Prowse, 2013, Component pathogen inactivation: a critical review, Vox Sang, 104, 183, 10.1111/j.1423-0410.2012.01662.x van Rhenen, 2003, Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial, Blood, 101, 2426, 10.1182/blood-2002-03-0932 Snyder, 2005, Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: The SPRINT trial, Transfusion, 45, 1864, 10.1111/j.1537-2995.2005.00639.x Mirasol Clinical Evaluation Study Group, 2010, A randomized controlled clinical trial evaluating the performance and safety of platelets treated with Mirasol pathogen reduction technology, Transfusion, 50, 2362, 10.1111/j.1537-2995.2010.02694.x McCullough, 2004, Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial, Blood, 104, 1534, 10.1182/blood-2003-12-4443 Sanquin Vamvakas, 2012, Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system, Vox Sang, 102, 302, 10.1111/j.1423-0410.2011.01555.x Butler, 2013, Pathogen-reduced platelets for the prevention of bleeding, Cochrane Database Syst Rev, 3, Cd009072 Van Aelst, 2015, Ultraviolet C light pathogen inactivation treatment of platelet concentrates preserves integrin activation but affects thrombus formation kinetics on collagen in vitro, Transfusion, 55, 2404, 10.1111/trf.13137 Tauszig, 2012, Platelet derived cytokine accumulation in platelet concentrates treated for pathogen reduction, Transfus Apher Sci, 46, 33, 10.1016/j.transci.2011.10.025 Bakkour, 2014, Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light, Vox Sang, 107, 351, 10.1111/vox.12173 Bashir, 2013, Pathogen inactivation of platelets using ultraviolet C light: Effect on in vitro function and recovery and survival of platelets, Transfusion, 53, 990, 10.1111/j.1537-2995.2012.03854.x Picker, 2009, Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study, Transfus Apher Sci, 40, 79, 10.1016/j.transci.2009.01.013 Johnson, 2015, Treatment of Platelet Concentrates with the Mirasol Pathogen Inactivation System Modulates Platelet Oxidative Stress and NF-kappaB Activation, Transfus Med Hemother, 42, 167, 10.1159/000403245 Osman, 2015, Differential Expression Analysis by RNA-Seq Reveals Perturbations in the Platelet mRNA Transcriptome Triggered by Pathogen Reduction Systems, PLoS One, 10, e0133070, 10.1371/journal.pone.0133070 Osman, 2015, Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function, Platelets, 26, 154, 10.3109/09537104.2014.898178 Prudent, 2014, Proteome changes in platelets after pathogen inactivation--an interlaboratory consensus, Transfus Med Rev, 28, 72, 10.1016/j.tmrv.2014.02.002 Chen, 2014, p38MAPK is involved in apoptosis development in apheresis platelet concentrates after riboflavin and ultraviolet light treatment, Transfusion, 55, 848 Schubert, 2013, Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment, Transfusion, 53, 3164, 10.1111/trf.12173 Henschler, 2011, Development of the S-303 Pathogen Inactivation Technology for Red Blood Cell Concentrates, Transfus Med Hemother, 38, 33, 10.1159/000324458 Ruane, 2004, Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light, Transfusion, 44, 877, 10.1111/j.1537-2995.2004.03355.x Tonnetti, 2012, Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood, Transfusion, 52, 409, 10.1111/j.1537-2995.2011.03285.x Tonnetti, 2013, Riboflavin and ultraviolet light reduce the infectivity of Babesia microti in whole blood, Transfusion, 53, 860, 10.1111/j.1537-2995.2012.03791.x Owusu-Ofori, 2015, Treatment of Whole Blood With Riboflavin and UV Light: Impact on Malaria Parasite Viability and Whole Blood Storage, Shock, 44, 33, 10.1097/SHK.0000000000000280 Cancelas, 2011, In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood, Transfusion, 51, 1460, 10.1111/j.1537-2995.2010.03027.x Schubert, 2014, Whole blood treated with riboflavin and ultraviolet light: Quality assessment of all blood components produced by the buffy coat method, Transfusion, 55, 815, 10.1111/trf.12895 Custer, 2015, Alliance of Blood Operators Risk-Based Decision-Making I. Health economics and outcomes methods in risk-based decision-making for blood safety, Transfusion, 55, 2039, 10.1111/trf.13080 Goodell, 2014, Costs, consequences, and cost-effectiveness of strategies for Babesia microti donor screening of the US blood supply, Transfusion, 54, 2245, 10.1111/trf.12805 Janssen, 2006, Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands, Transfusion, 46, 956, 10.1111/j.1537-2995.2006.00828.x Bell, 2003, Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States, Clin Ther, 25, 2464, 10.1016/S0149-2918(03)80288-6 Custer, 2010, The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model, Transfusion, 50, 2461, 10.1111/j.1537-2995.2010.02704.x Agapova, 2015, Introducing Pathogen Reduction Technology in Poland: A Cost-Utility Analysis, Transfus Med Hemother, 42, 158, 10.1159/000371664 Murphy, 2011, Pathogen reduction: State of reflection in Ireland, Transfus Clin Biol, 18, 488, 10.1016/j.tracli.2011.05.004 Berger, 2013, Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates, Onkologie, 36, 53, 10.1159/000346309 Girona-Llobera, 2014, Reducing the financial impact of pathogen inactivation technology for platelet components: Our experience, Transfusion, 54, 158, 10.1111/trf.12232 Veihola, 2006, Variation of platelet production and discard rates in 17 blood centers representing 10 European countries from 2000 to 2002, Transfusion, 46, 991, 10.1111/j.1537-2995.2006.00832.x Cerus Corporation TerumoBCT, 2012 Seghatchian, 2011, Main Properties of the Theraflex MB-Plasma System for Pathogen Reduction, Transfus Med Hemother, 38, 55, 10.1159/000323786 Macopharma Canadian Agency for Drugs and Technologies in Health, 2011, CADTH Optimal Use Reports Seghatchian, 2012, Characteristics of the Theraflex UV-Platelets pathogen inactivation system - An update, Transfus Apher Sci, 46, 221, 10.1016/j.transci.2012.01.008